Abstract

A recent study has found that PSA recurrence rate for clinical T1c tumors is similar to T2 tumors, indicating a need for further refinement of clinical staging system. To test this finding we compared clinicopathologic characteristics and the time to PSA progression following radical retropubic prostatectomy of patients with clinical stage T1c tumors to those with stage T2, T2a or T2b tumors. From a total of 186 consecutive patients submitted to prostatectomy, 33.52% had clinical stage T1c tumors, 45.45% stage T2a tumors and 21.02% stage T2b tumors. The variables studied were age, preoperative PSA, prostate weight, Gleason score, tumor extent, positive surgical margins, extraprostatic extension (pT3a), seminal vesicle invasion (pT3b), and time to PSA progression. Tumor extent was evaluated by a point-count method. Patients with clinical stage T1c were younger and had the lowest mean preoperative PSA. In the surgical specimen, they had higher frequency of Gleason score < 7 and more organ confined cancer. In 40.54% of the patients with clinical stage T2b tumors, there was extraprostatic extension (pT3a). During the study period, 54 patients (30.68%) developed a biochemical progression. Kaplan-Meier product-limit analysis revealed no significant difference in the time to PSA progression between men with clinical stage T1c versus clinical stage T2 (p = 0.7959), T2a (p = 0.6060) or T2b (p = 0.2941) as well as between men with clinical stage T2a versus stage T2b (p = 0.0994). Clinicopathological features are not similar considering clinical stage T1c versus clinical stages T2, T2a or T2b.

Highlights

  • A recent study [1] has found that PSA recurrence rate for clinical T1c tumors is similar to T2 tumors, indicating a need for further refinement of clinical staging system

  • The study was done on 59 patients with clinical stage T1c tumors and 127 patients with clinical stage T2 tumors submitted to radical retropubic pros

  • There were no statistically significant differences related to age (p = 0.0788), preoperative PSA (p = 0.3791), prostate weight (p = 0.6301), tumor extent (p = 0.1857), positive surgical margins (p = 0.3163), extraprostatic extension (p = 0.1020) and seminal vesicle invasion (p = 0.2481)

Read more

Summary

INTRODUCTION

A recent study [1] has found that PSA recurrence rate for clinical T1c tumors is similar to T2 tumors, indicating a need for further refinement of clinical staging system. To test this finding we compared clinicopathologic characteristics and the time to PSA progression following radical prostatectomy of patients with clinical T1c tumors to those with T2 tumors as well as subclassifying stage T2 into stages T2a and T2b

MATERIAL AND METHODS
RESULTS
CONCLUSIONS
International Union Against Cancer
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call